Obinutuzumab with mycophenolate mofetil for treating lupus nephritis

Obinutuzumab in combination with mycophenolate mofetil is in clinical development for the
treatment of class III or class IV lupus nephritis (LN) in adults. LN is a manifestation of a disease
called systemic lupus erythematosus (SLE). In LN, the immune system (the body’s natural
defences) attacks the kidneys, causing inflammation and kidney damage. LN remains a substantial
cause of morbidity and mortality in lupus patients. Treatment of LN has been challenged by the
limited number of effective medicinal products and side-effects associated with them.